BR0211320A - Formulação otimizada de tobramicina para aerossolização - Google Patents

Formulação otimizada de tobramicina para aerossolização

Info

Publication number
BR0211320A
BR0211320A BR0211320-1A BR0211320A BR0211320A BR 0211320 A BR0211320 A BR 0211320A BR 0211320 A BR0211320 A BR 0211320A BR 0211320 A BR0211320 A BR 0211320A
Authority
BR
Brazil
Prior art keywords
formulation
aerosolization
tobramycin
optimized
optimized formulation
Prior art date
Application number
BR0211320-1A
Other languages
English (en)
Other versions
BRPI0211320B1 (pt
BRPI0211320B8 (pt
Inventor
Chiara Malvotti
Raffaella Garzia
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8177921&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0211320(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of BR0211320A publication Critical patent/BR0211320A/pt
Publication of BRPI0211320B1 publication Critical patent/BRPI0211320B1/pt
Publication of BRPI0211320B8 publication Critical patent/BRPI0211320B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

"FORMULAçãO OTIMIZADA DE TOBRAMICINA PARA AEROSSOLIZAçãO". A invenção apresenta uma formulação de tobramicina para deposição por meio de aerossolização na forma de solução isotónica livre de aditivos cujo pH foi otimizado a fim de assegurar uma adequada vida útil em temperatura ambiente. A mencionada formulação pode ser utilizada de modo vantajoso para o tratamento e a profilaxia de infecções endobrónquicas agudas e crónicas, especialmente aquelas causadas pela bactéria Pseudomonas aeruginosa associada com doenças pulmonares tal como a fibrose cística.
BRPI0211320A 2001-07-02 2002-06-14 formulação de tobramicina para aerossolização BRPI0211320B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116071A EP1273292B1 (en) 2001-07-02 2001-07-02 Optimised formulation of tobramycin for aerosolization
PCT/EP2002/006544 WO2003004005A1 (en) 2001-07-02 2002-06-14 Optimised formulation of tobramycin for aerosolization

Publications (3)

Publication Number Publication Date
BR0211320A true BR0211320A (pt) 2004-09-28
BRPI0211320B1 BRPI0211320B1 (pt) 2015-08-18
BRPI0211320B8 BRPI0211320B8 (pt) 2021-05-25

Family

ID=8177921

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0211320A BRPI0211320B8 (pt) 2001-07-02 2002-06-14 formulação de tobramicina para aerossolização

Country Status (27)

Country Link
US (5) US6987094B2 (pt)
EP (1) EP1273292B1 (pt)
JP (1) JP4262086B2 (pt)
KR (1) KR100910888B1 (pt)
CN (1) CN1234346C (pt)
AT (1) ATE267591T1 (pt)
AU (1) AU2002319226B2 (pt)
BG (1) BG66328B1 (pt)
BR (1) BRPI0211320B8 (pt)
CA (1) CA2452638C (pt)
CZ (1) CZ299348B6 (pt)
DE (1) DE60103527T2 (pt)
DK (1) DK1273292T3 (pt)
EA (1) EA006068B1 (pt)
EE (1) EE05392B1 (pt)
EG (1) EG24019A (pt)
ES (1) ES2222294T3 (pt)
HK (1) HK1068784A1 (pt)
HU (1) HU230807B1 (pt)
PL (1) PL202598B1 (pt)
PT (1) PT1273292E (pt)
SI (1) SI1273292T1 (pt)
SK (1) SK285806B6 (pt)
TN (1) TNSN03149A1 (pt)
TR (1) TR200401980T4 (pt)
WO (1) WO2003004005A1 (pt)
ZA (1) ZA200400026B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
PT1458360E (pt) 2001-12-19 2011-07-13 Novartis Ag Derivados de indole como agonistas do recetor s1p1
PT3536344T (pt) * 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
ATE350024T1 (de) * 2003-10-15 2007-01-15 Pari Gmbh Flüssige zubereitung enthaltend tobramycin
US8442280B2 (en) * 2004-01-21 2013-05-14 Edda Technology, Inc. Method and system for intelligent qualitative and quantitative analysis of digital radiography softcopy reading
PT2316419E (pt) 2004-05-17 2012-10-22 Gilead Sciences Inc Combinação de fosfomicina/aminoglicósido em aerossol para o tratamento de infeções respiratórias bacterianas
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
AU2006297289B2 (en) * 2005-09-29 2013-03-21 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US20090246146A1 (en) * 2008-01-25 2009-10-01 Botond Banfi Halides in the treatment of pathogenic infection
WO2010042549A1 (en) 2008-10-07 2010-04-15 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
CA2752296C (en) * 2009-02-18 2018-09-11 Aradigm Corporation Ph-modulated formulations for pulmonary delivery
ES2739979T3 (es) 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
EP2388008A1 (en) 2010-05-14 2011-11-23 Combino Pharm, S.L. Stable, preservative-free, aqueous formulation for the administration by aerosolization comprising tobramycin
MX336260B (es) 2010-07-12 2016-01-13 Xellia Pharmaceuticals Aps Composiciones para el tratamiento de infecciones de pulmon, formuladas para ser administrables mediante aerolizacion, y que incluyen tobramicina.
US9271993B2 (en) * 2010-09-13 2016-03-01 University Of Zurich Treatment of bacterial infectious diseases
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
DK2670242T3 (da) * 2011-01-31 2022-05-02 Avalyn Pharma Inc Aerosolpirfenidon- og pyridonanalogforbindelser og anvendelser deraf
EP2567691B1 (en) 2011-09-12 2014-12-24 Meiji Seika Pharma Co., Ltd. Aqueous compositions comprising arbekacin
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
CN105534961B (zh) * 2015-12-30 2019-06-04 孙红娟 妥布霉素吸入溶液及其制备方法
CN105616345B (zh) * 2016-03-01 2018-08-21 上海方予健康医药科技有限公司 一种妥布霉素吸入组合物及其制备方法和用途
EP3551191A4 (en) * 2016-12-09 2020-09-09 EnBiotix, Inc. POTENTIALIZATION OF AMINOGLYCOSIDE FOR THE TREATMENT OF BACTERIAL PULMONARY INFECTION
CN108014099B (zh) * 2017-12-15 2019-03-01 武汉兴华智慧医药科技有限公司 一种吸入用妥布霉素溶液及其制备方法
GB2565941A (en) * 2018-11-27 2019-02-27 Norton Healthcare Ltd A process for preparing a formulation
CN113018443B (zh) * 2019-12-27 2022-09-13 海南斯达制药有限公司 治疗呼吸***疾病的药物组合物及其制备方法
CN113952320B (zh) * 2021-09-18 2022-03-18 健康元药业集团股份有限公司 一种包含妥布霉素吸入溶液的药物组件及其用途

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3361306A (en) 1966-03-31 1968-01-02 Merck & Co Inc Aerosol unit dispensing uniform amounts of a medically active ingredient
US3622053A (en) 1969-12-10 1971-11-23 Schering Corp Aerosol inhaler with flip-up nozzle
MX3864E (es) 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4185100A (en) 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
US4499108A (en) 1983-06-08 1985-02-12 Schering Corporation Stable pleasant-tasting albuterol sulfate pharmaceutical formulations
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IT1196142B (it) 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
US4584320A (en) 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
IE67185B1 (en) 1990-02-02 1996-03-06 Fisons Plc Propellant compositions
WO1992011236A1 (en) 1990-12-19 1992-07-09 Smithkline Beecham Corporation Aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5190029A (en) 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
KR100229975B1 (ko) 1991-05-21 1999-11-15 스티븐 에프. 웨인스톡 에어로졸 흡입장치
DE59209686D1 (de) 1991-08-29 1999-06-02 Broncho Air Medizintechnik Ag Medizinisches gerät zur inhalation von dosier-aerosolen
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressed aerosol preparations
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
ES2099415T3 (es) 1991-12-18 1997-05-16 Minnesota Mining & Mfg Formulaciones de aerosol en suspension.
DE4230876A1 (de) 1992-03-17 1993-09-23 Asta Medica Ag Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
WO1994013262A1 (en) 1992-12-09 1994-06-23 Boehringer Ingelheim Pharmaceuticals, Inc. Stabilized medicinal aerosol solution formulations
SE9203743D0 (sv) 1992-12-11 1992-12-11 Astra Ab Efficient use
WO1994014490A1 (de) 1992-12-23 1994-07-07 Bernhard Hugemann Verfestigter arzneistoffvorrat für die mechanische erzeugung inhalierbarer wirkstoffpartikel
US5569450A (en) 1993-03-17 1996-10-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
EP0689423B1 (en) 1993-03-17 1997-09-17 Minnesota Mining And Manufacturing Company Aerosol formulation containing a diol-diacid derived dispersing aid
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
DK0735884T3 (da) 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
GB9425160D0 (en) 1994-12-10 1995-02-08 Glaxo Group Ltd Medicaments
MX9704550A (es) 1994-12-22 1997-10-31 Astra Ab Formulaciones de medicamentos en aerosol.
GB9426252D0 (en) 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
DE4446891A1 (de) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stabile wäßrige Budesonid-Lösung
US5653961A (en) 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
TR199701167T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol i�in �l��lm�� doz inhaleri.
SK284448B6 (sk) 1995-04-14 2005-04-01 Glaxo Wellcome Inc. Merací dávkovací inhalátor
NZ306281A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate
CA2217954C (en) 1995-04-14 2005-02-15 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
JP2000514085A (ja) 1996-07-08 2000-10-24 ローヌ―プーラン・ロウラー・リミテッド 医薬シクロスポリンａエーロゾル溶液処方物
AU3811897A (en) 1996-07-24 1998-02-10 Oglios Therapeutics, Inc. Antisense oligonucleotides as antibacterial agents
GB9616237D0 (en) 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
US6413496B1 (en) 1996-12-04 2002-07-02 Biogland Ireland (R&D) Limited Pharmaceutical compositions and devices for their administration
ATE301991T1 (de) 1996-12-04 2005-09-15 Link Products Ltd Arzneimittel zusammensetzungen und vorrichtungen zu deren verabreichung
DK1014943T3 (da) 1997-02-05 2002-10-14 Jago Res Ag Medicinske aerosolformuleringer
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5891419A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
GB2326334A (en) 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
BR7702049U (pt) 1997-09-05 1999-09-14 Chiesi Farma Spa Bico pulverizador para utilização em inalador oral para medicamentos aerossóis
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
US6045784A (en) 1998-05-07 2000-04-04 The Procter & Gamble Company Aerosol package compositions containing fluorinated hydrocarbon propellants
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
US6451285B2 (en) 1998-06-19 2002-09-17 Baker Norton Pharmaceuticals, Inc. Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
DE19847969A1 (de) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Lagerfähig flüssige Formulierung mit Formoterol
PT1283036E (pt) 1998-11-13 2008-03-06 Jagotec Ag Inalador de pó seco de dose múltipla com um reservatório de pó
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
IT1303788B1 (it) 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6290930B1 (en) 1998-12-18 2001-09-18 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes and budesonide
US6004537A (en) 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IT1318514B1 (it) 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
SK286694B6 (sk) 2000-05-22 2009-03-05 Chiesi Farmaceutici S.P.A. Aerosólový farmaceutický prostriedok
ES2222294T3 (es) * 2001-07-02 2005-02-01 Chiesi Farmaceutici S.P.A. Formulacion optimizada de tobramicina para administracion en forma de aerosol.
EP1340492A1 (en) 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Aerosol formulations for pulmonary administration of medicaments having systemic effects
PT3536344T (pt) 2002-03-01 2020-03-26 Chiesi Farm Spa Formulação superfina de formoterol
EP1415647A1 (en) 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
US20050083693A1 (en) * 2003-10-21 2005-04-21 Timothy Garrett Flag illumination fixture

Also Published As

Publication number Publication date
JP4262086B2 (ja) 2009-05-13
CA2452638A1 (en) 2003-01-16
AU2002319226B2 (en) 2006-07-06
JP2004535454A (ja) 2004-11-25
CN1234346C (zh) 2006-01-04
EG24019A (en) 2008-03-25
CN1529589A (zh) 2004-09-15
US20120184502A1 (en) 2012-07-19
EE200400050A (et) 2004-04-15
TR200401980T4 (tr) 2004-09-21
SK16432003A3 (sk) 2004-06-08
WO2003004005A1 (en) 2003-01-16
US20040186064A1 (en) 2004-09-23
KR100910888B1 (ko) 2009-08-05
HUP0400387A2 (hu) 2004-09-28
BRPI0211320B1 (pt) 2015-08-18
US6987094B2 (en) 2006-01-17
US7696178B2 (en) 2010-04-13
ATE267591T1 (de) 2004-06-15
PT1273292E (pt) 2004-10-29
US20110212912A1 (en) 2011-09-01
HK1068784A1 (en) 2005-05-06
SK285806B6 (sk) 2007-08-02
EP1273292B1 (en) 2004-05-26
DE60103527D1 (de) 2004-07-01
DE60103527T2 (de) 2005-06-16
CZ299348B6 (cs) 2008-06-25
EA006068B1 (ru) 2005-08-25
US20050163722A1 (en) 2005-07-28
US8168598B2 (en) 2012-05-01
SI1273292T1 (en) 2004-12-31
EP1273292A1 (en) 2003-01-08
BRPI0211320B8 (pt) 2021-05-25
KR20040018403A (ko) 2004-03-03
HU230807B1 (hu) 2018-06-28
DK1273292T3 (da) 2004-10-04
EE05392B1 (et) 2011-04-15
TNSN03149A1 (en) 2005-12-23
BG66328B1 (bg) 2013-06-28
CA2452638C (en) 2010-10-05
BG108475A (en) 2005-02-28
PL202598B1 (pl) 2009-07-31
ZA200400026B (en) 2005-03-30
US7939502B2 (en) 2011-05-10
EA200301305A1 (ru) 2004-06-24
US20100098642A1 (en) 2010-04-22
PL367139A1 (en) 2005-02-21
CZ20033580A3 (cs) 2004-10-13
ES2222294T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
BR0211320A (pt) Formulação otimizada de tobramicina para aerossolização
CO5630025A2 (es) Derivados de carbostirilo y estabilizantes del estado de animo para tratar trastornos del mismo
UY25330A1 (es) Nuevos macrólidos
BR0313670A (pt) Composição ácida para limpeza pesada de superfìcies
BRPI0518406A2 (pt) composiÇÕes tendo uma alta eficÁcia antiviral e antibacteriana
ES2318119T3 (es) Procedimiento y composiciones para alterar el perfil del efecto edulcorante de la sucralosa.
BR112013021408A2 (pt) artigo recoberto incluindo revestimento de baixa emissividade, unidade de vidro de isolamento incluindo o artigo recoberto e/ou métodos de produção do mesmo
EP1560488A4 (en) ANTIBACTERIAL AGENTS
DK1322648T3 (da) 3-(heteroarylacetamido)-2-oxo-azetidin-1-sulfonsyrederivater som antibakterielle midler
DE60113851D1 (de) Bakteriophage mit breitem wirtspektrum
HUP0400446A2 (hu) Azitromicin kristályformái
NO20042271L (no) Formuleringer som inneholder en cefalosporinforbindelse og deres anvendelse for behandling av bakterielle infeksjoner i katter og hunder
BR112013000114A2 (pt) composição de limpeza e processo para limpeza de um substrato
TW200630367A (en) Substituted adenines and the uses thereof
EP1560821B8 (en) Antibacterial agents
CL2008001469A1 (es) Uso de compuestos derivado de 3,5-bitenil-1,2,4-triazol para el tratamiento de la formacion de biopeliculas de p.aeruginosa en un paciente con fibrosis quistica; y combinacion farmaceutica que comprende un compuesto de formula i y un antibiotico seleccionado de gentamicina,amicacina, tobramicina, ciprofloxacino, entre otros.
ATE437598T1 (de) Dichtung für eine duschabtrennung
AR013411A1 (es) Composicion de aplicacion para tratamientos antivirales y afecciones micosicas y/o bacterianas y utilizacion de dichas composiciones.
ATE412862T1 (de) Kühlvorrichtung
BR0100228A (pt) Macrolìdeos com 13 e 14 elementos antibacterianos e procinéticos e seus intermediários
BR9806100A (pt) Composição de vidro do tipo sílico-sodo-cálcico.
SG164382A1 (en) Use of azithromycin for the production of a medicament for treatment of ocular infections
UA27643U (en) Method for treatment of community-acquired pneumonia in children
GT199600072A (es) Formas zwitterionicas de trovafloxacina.
BRPI0411749A (pt) método para a inibição do crescimento de bactérias resistentes a antibióticos pelo uso de pentano-1,5-diol

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/08/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/06/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 14/06/2022